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Abstract
Background: The prevalence of diabetes is increasing in all industrialized countries and its prevention has become a public
health priority. However, the predictors of diabetes risk are insufficiently understood. We evaluated, whether 31 novel
biomarkers could help to predict the risk of incident diabetes.
Methods and Findings: The biomarkers were evaluated primarily in the FINRISK97 cohort (n=7,827; 417 cases of clinically
incident diabetes during the follow-up). The findings were replicated in the Health 2000 cohort (n=4,977; 179 cases of
clinically incident diabetes during the follow-up). We used Cox proportional hazards models to calculate the relative risk of
diabetes, after adjusting for the classic risk factors, separately for each biomarker. Next, we assessed the discriminatory
ability of single biomarkers using receiver operating characteristic curves and C-statistics, integrated discrimination
improvement (IDI) and net reclassification improvement (NRI). Finally, we derived a biomarker score in the FINRISK97 cohort
and validated it in the Health 2000 cohort. A score consisting of adiponectin, apolipoprotein B, C-reactive protein and
ferritin almost doubled the relative risk of diabetes in the validation cohort (HR per one standard deviation increase 1.88,
p=2.8 e-5). It also improved discrimination of the model (IDI=0.0149, p,0.0001) and reclassification of diabetes risk
(NRI=11.8%, p=0.006). Gender-specific analyses suggested that the best score differed between men and women. Among
men, the best results were obtained with the score of four biomarkers: adiponectin, apolipoprotein B, ferritin and
interleukin-1 receptor antagonist, which gave an NRI of 25.4% (p,0.0001). Among women, the best score included
adiponectin, apolipoprotein B, C-reactive protein and insulin. It gave an NRI of 13.6% (p=0.041).
Conclusions: We identified novel biomarkers that were associated with the risk of clinically incident diabetes over and
above the classic risk factors. This gives new insights into the pathogenesis of diabetes and may help with targeting
prevention and treatment.
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Introduction
Diabetes and its complications have become a major public
health problem in all western countries. It was estimated that 12.9%
of the U.S. population aged $20 years had diabetes in 2005–2006
and the proportion increased to 31.6% in persons aged $65 years
[1].Itiswellknownthatdiabetesincreasesthe riskofcoronaryheart
disease by 2–3 fold in men and by 3–4 fold in women [2], [3]. It also
increasesthe riskofstrokeby1.5–4 fold and accountsfor35–45%of
cases of end-stage renal failure [4], [5]. Recent research has shown
that the onset of type 2 diabetes can be postponed or prevented with
lifestyle intervention or by medication [6], [7]. Identifying
individuals at high risk of diabetes has therefore become a priority
for targeting preventive measures effectively.
Several risk equations based on lifestyle factors [8], classic
clinical risk factors [9] and genetic factors [10], [11] have been
proposed and tested for the prediction of diabetes. The
performance of these equations is fairly good but none has been
established for general use. Instead, several novel biomarkers have
been proposed both to improve clinical prediction and to gain
better insight into the pathogenesis of type 2 diabetes [12], [13].
These have produced promising results but the inferences have
been limited by modest sample sizes, testing of one biomarker at a
time and the lack of independent validation.
We have analyzed 31 novel biomarkers to test whether a single
biomarker or a combined biomarker score could improve the
prediction of clinically incident diabetes over and above the
classical risk factors. We used a large, population-based cohort
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validated the best predictors in another, independent cohort.
Methods
Cohort Descriptions
FINRISK97 Cohort. FINRISK97 involved 25–74 year old
respondents to a survey conducted in five geographical areas in
Finland [14]. It is based on a representative probability sample,
drawn from the population register. The participants were
instructed to fast for at least four hours before the scheduled
examination and avoid heavy meals earlier that day. The median
length of fasting was 5 hours (interquartile range 4–6 hours). The
survey included a mailed questionnaire and a clinical examination.
A blood sample was drawn for the measurement of serum lipids
and gamma glutamyl transferase (GGT). Altogether, 8,444
persons participated and gave written informed consent. A
detailed description of the cohort and methods is available on
the MORGAM web-site at http://www.ktl.fi/publications/
morgam/cohorts/full/finland/fin-fina.htm.
Health 2000 Cohort. Health 2000 was based on a stratified
two-stage cluster sampling from the population register to
represent the total Finnish population aged 30 years and over
[15]. A detailed Methodology Report is available on the world-
wide web (http://www.terveys2000.fi/doc/methodologyrep.pdf).
The fasting instructions were similar to those of FINRISK97. The
median length of fasting was 6.8 hours, interquartile range 5.6 –
13.5 hours). The survey included an interview on medical history,
and health-related lifestyle habits, and a clinical examination. A
blood sample was drawn from an antecubital vein. 6,200 persons
participated and gave a written informed consent.
Ethics. Both FINRISK97 and Health 2000 studies were
approved by the Ethics Committee of the National Public Health
Institute and carried out according to the recommendations of the
Declaration of Helsinki.
Diabetes at baseline. We used several data sources to
ascertain cases of prevalent diabetes at baseline: (a) self-report of
doctor-diagnosed diabetes or impaired glucose tolerance in the
questionnaire, (b) the national drug reimbursement records and
the National Hospital Discharge Register were checked for
reimbursements of purchases of hypoglycemic drugs or
hospitalizations with diabetes as the main or an additional
diagnosis, and (c) blood glucose $7 mmol/L at baseline. If any
of these sources was positive, the person was considered as having
prevalent diabetes and was excluded from the analyses. Altogether
617 persons with prevalent diabetes were excluded in FINRISK97
and 7,827 persons were included in the analyses. In the Health
2000 Study, 1,224 persons were excluded either because of
prevalent diabetes or age less than 35 or higher than 84 years.
Thus, 4,976 persons were included in the analyses.
Follow-up for incident diabetes. The follow-up was until
the end of 2007 for both cohorts. The median follow-up time was
10.8 years for the FINRISK97 and 7.1 years for the Health 2000
cohort. Clinically incident diabetes was the main outcome of
interest. Three data sources were used to identify cases of clinically
incident diabetes during the follow-up. (1) Record linkage of the
study data with the National Drug Reimbursement Register on the
basis of the personal identification code unique to each individual
in the country. In Finland, persons with diabetes receive their
hypoglycemic medications free of charge. To obtain this right, the
person must present a statement from his/her physician
documenting the clinical and laboratory findings that led to the
diagnosis of diabetes. This statement is then reviewed by an expert
physician of the National Social Insurance Institute and, if the
documentation is found adequate, the right to the full
reimbursement is granted. The Social Insurance Institute keeps
a country-wide register of persons entitled to these
reimbursements. (2) Record linkage with the National Hospital
Discharge Register, which includes all hospitalizations in Finland
(main diagnosis and up to four additional diagnoses). We checked
whether diabetes (ICD-10 code E10-E14) was listed as any of the
diagnoses for a hospitalization during the follow-up. (3) Record
linkage with the National Causes-of-Death Register, which
includes all deaths of permanent residents of Finland. We
checked whether diabetes (ICD-10 code E10-E14) was
mentioned as any of the causes of death (underlying cause of
death, direct cause of death, or the contributing causes of death). If
diabetes was found in any of these data sources, the person was
considered to have incident diabetes. The date when the diabetes
diagnosis first appeared was taken as the date of onset of diabetes.
These procedures identify all cases of diabetes that were treated
with hypoglycemic medications or hospitalized or who died during
the follow-up. However, diabetic patients treated with diet only,
who were not hospitalized and did not die, were not identified by
these procedures.
In all, 417 cases of incident diabetes (249 in men and 168 in
women) were observed in the FINRISK97 cohort and 179 cases
(95 in men and 84 in women) in the Health 2000 cohort.
Laboratory Methods
Most biomarkers were determined at the MORGAM Biomark-
er Laboratory, University of Mainz, Germany, from frozen,
unthawed samples stored at 270uC, using methods that are
described in more detail in the supporting information (Table S1).
Apolipoprotein B100 (apoB), C-reactive protein (CRP), homocys-
teine and hemoglobin A1c (HbA1c) in the Health 2000 cohort as
well as GGT in both cohorts were determined in the laboratories
of the National Health and Welfare Institute, Turku and Helsinki,
Finland, using routine commercial methods. Altogether, 31
biomarkers were determined in FINRISK97 and 10 were further
determined in Health 2000 to replicate the findings on single
biomarkers and to validate the performance of the biomarker
score. Classic risk factors were determined locally using routine
methods that have been described (http://www.terveys2000.fi/
doc/methodologyrep.pdf) and [14].
Statistical Methods
The analysis strategy comprised three stages: First, assessment of
the associations between the single biomarkers and incident
diabetes; second, assessment of the discriminative ability of single
biomarkers in risk prediction models; and third, derivation of a
composite biomarker score and its validation. In the first two
stages, the assessment was done primarily in the FINRISK97
cohort and replicated in the Health 2000 cohort. In the third
stage, the derivation of the biomarker score was based on the
FINRISK97 cohort and it was validated in the Health 2000
cohort. We derived the biomarker score on the basis of: (a) the
strength of association and reclassification in FINRISK; (b)
considering biological plausibility; (c) correlations between the
biomarkers to avoid including multiple biomarkers that reflect the
same biological process, and (d) availability of the biomarkers in
question in the validation cohort. Based on these criteria, we
experimented with a few potential scores in the training sample
taking into account both relative risk estimates and the net
reclassification improvement by the score, and proceeded with the
best ones to the validation sample.
The aim in model building was the prediction of absolute risk
(10 years in FINRISK97 and 7 years in Health 2000).
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and the net reclassification improvement (NRI) and integrated
discrimination improvement (IDI) statistics [17]. In reclassification
analyses we used categories 0–4.9%, 5–9.9%, 10–19.9% and
$20% in FINRISK97. Since the follow-up time was shorter for
Health 2000, somewhat lower cutpoints were used: 0–2.9%, 3–
7.9%, 8–14.9% and $15%. Model calibration was tested using
the Hosmer-Lemeshow test with 10 risk groups. A more detailed
description of statistical methods is presented in the supporting text
(Text S1).
Results
Both FINRISK97 and Health 2000 cohorts consisted of middle-
aged persons with approximately equal numbers of men and
women (Table 1). The levels of classic risk factors were as expected
for a community-based middle-aged cohort. Geometric means of
measured biomarkers are shown for both cohorts and both sexes in
supporting information (Table S2). Correlation matrix between the
biomarkers and classic risk factors is presented for FINRISK97 in
supporting Table S3 and for Health 2000 in supporting Table S4.
In Cox proportional hazards regression models controlling for
classic risk factors (age as the time scale, sex, high density
lipoprotein (HDL) cholesterol, non-HDL cholesterol, triglycerides,
body mass index (BMI), systolic blood pressure, antihypertensive
medication, current smoking, blood glucose, and history of CVD
at baseline), four biomarkers were significantly associated with
incident diabetes in both cohorts: adiponectin inversely, and CRP,
interleukin-1 receptor antagonist (IL-1ra), and ferritin directly
(Fig. 1). Furthermore, apoB was strongly associated with incident
diabetes in FINRISK97 and had a borderline significant
association (p=0.053) in Health 2000. Additionally, seven other
biomarkers were significantly associated with incident diabetes in
FINRISK97. Two of them (GGT and insulin) were available for
replication, but were nonsignificant in Health 2000 (Fig. 1). Sex-
specific HRs are shown in supporting information (Figures S1 and
S2).
To gain a better understanding of potential pathophysiological
mechanisms, we further adjusted the model on ferritin for CRP.
This did not reduce the HR substantially (from 1.18, p=0.001, to
1.17, p=0.002, in FINRISK97 and from 1.18, p=0.031, to 1.17,
p=0.041, in Health 2000). Likewise, to control more fully for
obesity, the model on apoB was further adjusted for waist-to-hip
ratio. This had very little effect on HR (from 1.63, p=9.2 e-9, to
1.58, p=2.5 e-7, in FINRISK97 and from 1.52, p=0.053, to
1.50, p=0.057, in Health 2000). We also carried out a sensitivity
analysis adjusting for physical activity, but HRs of the novel
biomarkers remained essentially unchanged, although physical
activity itself was clearly protective.
For comparison it should be noted that the HR for BMI, after
adjusting for other classic risk factors, was in FINRISK97 1.95
(p=7.4 e-66). Interestingly, even after adjusting for blood glucose
and other classic risk factors, HbA1c was strongly associated with
incident diabetes in Health 2000 (HR=2.35, 95%CI 1.97 – 2.79,
p=6.2 e-19).
Discrimination
Adiponectin, interleukin-18 (IL-18) and insulin improved the C-
index significantly, albeit modestly, in FINRISK97. None of the
single biomarkers improved C-index in Health 2000. Adiponectin,
apoB, CK-MB, CRP, ferritin and IL-18 improved IDI in
FINRISK97, but none of them replicated in Health 2000.
Reclassification
The addition of single biomarkers to the classic risk factors in
FINRISK97, revealed that nine biomarkers improved classifica-
tion significantly. The strongest were apoB (NRI=8.7%,
p,0.0001) and adiponectin (NRI=6.7%, p=0.005). However,
no single biomarker improved classification in Health 2000.
Biomarker score and its validation in Health 2000 cohort
Based on the FINRISK97 results, we created a biomarker score
which, for men and women combined, consisted of a linear
Table 1. Baseline characteristics of study participants.
Characteristics FINRISK97 HEALTH 2000
Men Women Men Women
n (%) 3922 (50.1) 3905 (49.9) 2272 (45.7) 2704 (54.3)
Age (yrs)* 47.3 (37.8–60.9) 44.7 (35.6–57.0) 52.1 (43.9–61.7) 53.7 (44.3–64.5)
Body-mass index (kg/m
2)* 26.6 (24.3–29.0) 25.8 (22.7–28.7) 26.8 (24.4–29.2) 26.3 (23.1–29.6)
Waist-Hip Ratio* 0.92 (0.88–0.97) 0.80 (0.75–0.84) 0.97 (0.94–1.01) 0.86 (0.82–0.90)
Systolic blood pressure (mmHg)* 137.9 (126.0–151.0) 130.3 (117.0–144.0) 134.7 (122.0–147.0) 132.6 (118.0–147.5)
Diastolic blood pressure (mmHg)* 83.7 (77.0–92.0) 79.4 (73.0–87.0) 84.1 (78.0–92.0) 79.9 (73.0–87.0)
Hypertension, n (%) 1389 (35.4) 1346 (34.5) 1159 (51.0) 1253 (46.3)
Current smoker, n (%) 1036 (26.4) 678 (17.4) 724 (31.9) 561 (20.7)
Prevalence of CVD, n (%) 305 (7.8) 111 (2.8) 188 (8.3) 154 (5.7)
High blood pressure medication, n (%) 501 (12.8) 390 (10.0) 463 (20.4) 685 (25.3)
Serum glucose (mmol/L)* 5.1 (4.7–5.4) 4.9 (4.6–5.2) 5.5 (5.2–5.8) 5.3 (5.0–5.6)
Total-cholesterol (mmol/L)* 5.4 (4.8–6.2) 5.4 (4.7–6.1) 6.0 (5.3–6.7) 5.9 (5.2–6.7)
LDL-cholesterol (mmol/L)* 3.4 (2.9–4.1) 3.2 (2.7–3.9) 3.9 (3.4–4.7) 3.8 (3.2–4.6)
HDL-cholesterol (mmol/L)* 1.2 (1.0–1.4) 1.5 (1.3–1.8) 1.2 (1.0–1.4) 1.4 (1.2–1.7)
Triglycerides (mmol/L)* 1.4 (1.0–2.0) 1.1 (0.8–1.5) 1.5 (1.1–2.1) 1.3 (0.9–1.6)
* Presented as geometric mean and interquartile range (Q1, Q3).
doi:10.1371/journal.pone.0010100.t001
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2000 this score was associated with incident diabetes with an
adjusted HR of 1.88 (1.40 – 2.53, p=2.8 e-5) (Fig. 1). The score
also improved IDI significantly (change in IDI=0.0149,
p,0.0001), but the improvement in C-index did not quite reach
statistical significance (p=0.064) (Fig. 2a). The NRI was, however,
significant 11.8% (p=0.0061) (Table 2) [18], [19]. Calibration of
the prediction model was good (Fig. 2b). An analysis by gender
suggested that the best score differed between men and women.
Among men, the best results were obtained with the score of four
biomarkers: adiponectin, apoB, ferritin and IL-1ra, which gave an
NRI of 25.4% (p,0.0001) (supporting information, Table S5).
The corresponding IDI was 0.0432 (p,0.0001) and the C-index
also improved significantly from 0.784 to 0.828 (p=0.002).
Among women, the best results were obtained with the score
including four biomarkers, adiponectin, apoB, CRP and insulin.
This score gave an NRI of 13.6% (p=0.041) (Supporting
information, Table S5). IDI was also significant, 0.0188
(p=0.003) but the change in C-index remained modest and
nonsignificant (p=0.277) among women. Equations for the scores
in men, women and both genders combined are presented in
supporting information (Table S6).
Discussion
Without any doubt, obesity is the strongest single predictor of
diabetes risk in middle aged individuals. Our study showed,
however, that adiponectin, apoB, CRP, and ferritin improved the
prediction of diabetes consistently in two independent cohorts
even after taking BMI, blood glucose and other classic risk factors
into account. Data suggested even more substantial improvements
in gender-specific analyses. Among men, the score consisting of
four biomarkers, adiponectin, apoB, IL-1ra and ferritin, improved
net reclassification by 25% and measures of model discrimination
also improved clearly. Among women, the best score consisted of
adiponectin, apoB, CRP anf insulin, and gave an NRI of 14%.
Suggestive evidence was found in the FINRISK97 cohort for
seven other biomarkers, which may deserve further research.
These findings may help to identify persons at high risk of diabetes
and improve the targeting of preventive measures. Perhaps more
Figure 1. Hazard ratios (95% CI, per one SD) of clinically incident diabetes. FINRISK97 cohort (black solid lines) has 417 cases and 7,410
noncases. Selected biomarkers and the biomarker score were determined in the Health 2000 cohort (red dotted lines), which has 179 cases and
4,798 noncases. Data on men and women are combined. Adjusted for sex, non-HDL-cholesterol, HDL-cholesterol, triglycerides, BMI, systolic blood
pressure, current smoking, blood glucose, history of a cardiovascular disease event and use of antihypertensive medication. Age was used as the
time scale.
doi:10.1371/journal.pone.0010100.g001
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diabetes in middle-aged individuals and these pathways may also
be amenable to intervention.
Earlier attempts at creating algorithms for the prediction of
diabetes have mainly focused on routinely measured clinical risk
factors [8], [9], [20], [21]. Recently, however, Kolberg and
coworkers reported a case control study nested in a life-style
intervention trial on cardiovascular diseases[12]. They tested a
panel of 58 biomarkers in 160 cases and 472 controls and found
that six biomarkers (adiponectin, CRP, ferritin, interleukin-2
receptor A, glucose and insulin) helped to predict the 5-year risk of
incident diabetes. Many of these biomarkers are the same as in our
study, even though we added a validation in an independent
cohort to avoid overoptimism. Two other recent papers evaluated
a set of genetic variants in addition to the clinical risk factors [10],
[11]. In the Framingham Offspring Study NRI remained modest,
4.1% to 2.1%, depending on the model, but in the Malmo ¨
Preventive Project an NRI of 9% and in the Botnia project an
NRI of 20% (p=0.05) was achieved.
Several studies have tested single biomarkers in addition to the
classic risk factors, usually using a nested case-control design. By
far the most data exist on CRP, which has been associated with
future diabetes in multiple studies[12], [22], [23]. In agreement
with the present study, high adiponectin has predicted a low risk of
diabetes in different populations [24], [25]. Serum ferritin
concentration has been found to be an indicator of diabetes risk
in the European Prospective Investigation of Cancer (EPIC)-
Norfolk Study [26], the Nurses Health Study [27] and the
Atherosclerosis Risk in Communities (ARIC) Study [28]. In the
latter study, however, adjustment for BMI abolished the
association. To distinguish between the acute phase response
and the iron metabolism, we further adjusted for CRP, which did
not reduce the HR of ferritin substantially, supporting the concept
that the ferritin-diabetes association may not reflect the acute
phase response but mainly the iron metabolism. Interleukin-18
was significantly associated with increased risk of diabetes in the
German MONICA-KORA study, which is in agreement with our
findings in FINRISK97 [29]. Unfortunately, we did not have
interleukin-18 available for replication in Health 2000.
IL-1ra is an interesting cytokine, which was associated with
incident type 2 diabetes in a recent case-control analysis of the
Whitehall II Study [30]. In a clinical trial, recombinant IL-1ra
improved beta-cell function and glycemic control in patients with
type 2 diabetes [31]. In our study, Il-1ra was consistently
associated with incident diabetes in both cohorts, which agrees
with these earlier reports. Somewhat surprisingly, one of the
strongest predictors of diabetes was apoB. The most obvious
explanation for this association would be obesity, but controlling
for both BMI and waist- to-hip ratio did not reduce the association
substantially. The ‘common soil’ hypothesis suggests that diabetes
and CVD share common antecedents [32]. The possibility that
apoB could play a role in both seems to deserve more detailed
study.
The biomarkers identified in our study suggest at least three
interesting areas in the pathophysiology of diabetes, which warrant
further research. First, adiponectin is emerging as a potent
antidiabetic hormone. It is produced and secreted by adipocytes
but is inversely correlated with obesity. It increases insulin
sensitivity, improves glucose tolerance and inhibits inflammation.
However, the associations of adiponectin with cardiovascular and
total mortality are controversial, the majority of studies seem to
support increased, rather than decreased risk [12], [33]. Secondly,
ferritin was associated with increased risk of diabetes and the
association was particularly evident among men, whereas no
significant association was observed among women. This, together
with the fact that the association was robust to adjustment for
CRP, suggests a role for iron overload in the pathogenesis of
diabetes. Third, IL-1Ra was associated with increased risk of
Figure 2. ROC curves and C-index with and without the four biomarker score, and calibration of the model with the four biomarker
score. Health 2000 study. The score includes adiponectin, apoB, CRP, and ferritin. The model is adjusted for the same classic risk factors as in Fig. 1.
Age was used as the time scale.
doi:10.1371/journal.pone.0010100.g002
Table 2. Net reclassification improvement
* due to the biomarker score
{.
Predicted risk with biomarker score
Persons developing diabetes during
7-year follow-up (n=174)
,3% 3–7.9% 8–14.9% $15% up
{ down
{
,3% 29 (75.2%) 8 (22.2%) 1 (2.6%) 0 (0.0%)
3–7.9% 8 (11.0%) 48 (67.5%) 14 (19.4%) 1 (2.1%) 39 (21.0%) 22 (12.0%)
8–14.9% 0 (0.0%) 10 (23.6%) 17 (41.6%) 14 (34.8%)
$15% 0 (0.0%) 1 (3.3%) 4 (9.4%) 33 (87.2%)
Persons not developing diabetes during
7-year follow-up (n=4803)
,3% 3000 (95.8) 132 (4.2%) 0 (0.0%) 0 (0.0%)
3–7.9% 326 (27.0%) 766 (63.5%) 113 (9.4%) 2 (0.1%) 297 (6.2%) 433 (9.0%)
8–14.9% 3 (1.0%) 80 (25.6%) 180 (57.3%) 51 (16.2%)
$15% 1 (0.7%) 4 (2.7%) 18 (13.5%) 113 (83.0%)
*Net reclassification improvement 11.8% (SE 0.043), p=0.0061.
{The biomarker score consists of adiponectin, apolipoprotein B, C-reactive protein and ferritin. The conventional risk factor model included the same risk factors as in
Fig. 1. Coefficients from FINRISK97 are applied to the Health 2000 validation cohort. Men and women combined.
{The numbers of persons reclassified up and down do not exactly equal to the sum of different categories, because the reclassification analysis has been performed
using the Kaplan-Meier approach and the result has been rounded to the nearest integer.
doi:10.1371/journal.pone.0010100.t002
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may be compensatory to the increased production of proinflam-
matory IL-1 beta in the pancreas, which is known to induce beta
cell apoptosis and impair insulin secretion [28], [34].
The strengths of our study include a simultaneous evaluation of
a large panel of biomarkers, large cohorts, a prospective
population-based design and the validation of prediction in an
independent cohort. Certain limitations should also be mentioned.
First, even though we had altogether 590 cases of clinically
incident diabetes in our study, we had only 179 incident cases in
the validation cohort available for the analyses on seven-year
absolute risk of diabetes. Therefore, the numbers in gender-
specific analyses were smallish and these results need to be
confirmed in future studies. Secondly, the age range in the
validation cohort was wide, 35–84 years, which may have
attenuated the results since age alone is a strong risk factor and
the risk prediction usually works best in middle-aged individuals.
Thirdly, we could not analyze all 31 biomarkers in the Health
2000 cohort. We chose the most promising ones for replication
but, nevertheless, there were five biomarkers with significant HRs
in FINRISK97 that were not available for replication in Health
2000. Fourthly, we did not carry out oral glucose tolerance tests at
baseline or measure fasting blood glucose at a follow-up
examination. Our outcome was clinically incident diabetes,
identified through the use of hypoglycemic medications, diagnoses
for hospitalizations and causes of death. Therefore, we could not
identify clinically mild cases of diabetes, treated with diet only.
This may have reduced the statistical power slightly, but it is
unlikely that the predictors would have been different if we could
have included cases of diabetes treated with diet only.
In conclusion, after accounting for classic risk factors, our study
identified adiponectin, apoB, CRP, IL-1ra and ferritin as the
strongest predictors of incident diabetes. The biomarker score,
composed as a linear combination of four biomarkers, was
associated with doubling of the relative hazard of diabetes in the
independent validation cohort. The prediction of absolute risk of
diabetes produced a significantly improved net reclassification and
discrimination, especially in gender-specific analyses, with the
model including the biomarker score. This information may help
with identifying individuals at high risk of developing diabetes.
Perhaps more importantly, it may indicate directions which
further research on the pathogenesis and prevention of diabetes
should take.
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